Hypoparathyroidism and ADH1 Support in Australia
The Australian patient organisation for people living with hypoparathyroidism and Autosomal Dominant Hypocalcemia Type 1 (ADH1). We connect patients and families, share trusted information, and advocate for access to better treatments in Australia.
Free to join | Donations tax‑deductible | ACNC Registered | DGR Endorsed
“Living with hypoparathyroidism or ADH1 often means managing symptoms other people can’t see, like fatigue, brain fog and muscle cramps, alongside the constant work of keeping calcium levels stable. New treatments are arriving: one is already registered in Australia but not yet subsidised, and others are moving through trials and regulators. That’s why CaSR Patient Support exists: to make sure Australian patients aren’t left behind as these treatments become available.”
How We Make a Difference
CaSR Patient Support unites patients, researchers, clinicians, and policymakers to advocate for better treatment for hypoparathyroidism and ADH1.
Patient Resources
Guides, fact sheets, and support for patients and families living with hypoparathyroidism and ADH1.
Learn MoreResearch & Progress
Keeping patients and families informed about research into hypoparathyroidism and ADH1, including clinical trials they may be able to join.
CaSR Patient Support has received grant funding from BridgeBio Pharma, Inc. See our funding disclosure.
Learn MoreCampaigns & Advocacy
Advocating for timely access to new treatments in Australia, engaging government and representing patients’ needs to regulators and decision‑makers.
Learn MoreSupport Our Journey
Your tax-deductible donation funds patient support, trusted information, awareness and advocacy for treatment access. Together, we can advocate for access to better treatments for hypoparathyroidism and ADH1.
Donations received in the 2026-27 financial year. Grants are listed separately under Our funding and are not included.
Donations are tax‑deductible • DGR Endorsed
Industry support
BridgeBio Pharma, Inc.
In 2026 BridgeBio Pharma, Inc. provided CaSR Patient Support with a grant of AUD 15,000 for our Patient Advocacy & Engagement Initiative (October to December 2026). The grant supports patient meetups, patient education and advocacy, and patient engagement across Australia.
CaSR Patient Support keeps full editorial, educational and program independence. BridgeBio has no input into, or approval of, our advocacy positions, educational content or patient communications. Our patient education materials are reviewed by our Medical Advisory Board. Funding is not contingent on promoting any medicine or product.
Government grants
Australian Government, Department of Social Services
A 2025-26 Volunteer Grant of $2,750 supporting our volunteers (September 2026 to September 2027). Funded by the Australian Government Department of Social Services.
In-kind support
- Google Ad Grants: CaSR Patient Support is a participant in the Google Ad Grants program. Ad Grants offers eligible organizations access to up to $10,000 per month in Search ads shown on Google.com to help them connect to people searching for their mission, raise awareness, attract donors, and recruit new volunteers.
- Microsoft Azure: Cloud computing credit for nonprofits.
- Canva for Nonprofits: Free design software.
Grants and in-kind support are not donations and are not counted in the donations total.
Led by Experts, Driven by Patients
Our committee brings together clinical expertise, financial governance, and lived patient experience.
Small Amounts. Real Impact.
We are entirely volunteer‑run, so donations fund the work itself: patient support, patient resources and ongoing advocacy.
Patient submissions to government decision‑makers
Plain‑language patient information resources
TGA evaluation and PBS listing advocacy campaigns